Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

QTORIN rapamycin delivered positive Phase III results in microcystic lymphatic malformations, with 95% of 51 patients improving. Palvella has begun a rolling FDA NDA submission and is targeting completion by year-end, potentially supporting approval in the first half of 2027. Palvella is preparing for a U.S. launch, including plans to hire 40 sales representatives, and expects a potential annual treatment price of $100,000 to $200,000 per patient. The company has identified about 400 treatment centers serving an estimated 15,000 patients. The company is expanding QTORIN rapamycin into additional rare diseases, including cutaneous venous malformations and angiokeratomas, while advancing QTORIN pitavastatin. Management says its $251 million cash balance could fund six programs and potentially support operations toward cash-flow breakeven without near-term equity financing.

Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations. Speaking at the Canaccord Conference, Chief Executive Officer Wes Kaupinen said the company’s strategy is centered on delivering first approved therapies in underserved rare-disease settings. He said there are approximately 600 rare skin diseases, with fewer than 2% having approved therapies.

QTORIN rapamycin is Palvella’s 3.9% anhydrous topical formulation of the mTOR inhibitor rapamycin. The company is developing it initially for microcystic lymphatic malformations, or mLM, a rare genetic and lifelong condition involving malformed lymphatic vessels that protrude through the skin. Kaupinen said the condition can cause lymphatic-fluid discharge, compromised skin barriers, infections including acute cellulitis, bleeding and hospitalizations. He described the disease as progressive if left untreated and said it has no approved therapies. Palvella estimates there are more than 30,000 U.S. patients with mLM. In the company’s 51-patient Phase III study, 95% of patients improved on the Microcystic Lymphatic Malformation Investigator Global Assessment, according to Kaupinen. He said 86% of patients were rated “much improved” or “very much improved,” and that the study met its primary endpoint, key secondary endpoint and all prespecified secondary endpoints.

Palvella has held a pre-NDA meeting with the FDA and begun a rolling NDA submission. Kaupinen said the company is in the final quality-control stages, is not awaiting further data, and aims to complete the submission before year-end. He said the timeline puts the company on track for a first-half 2027 submission. QTORIN rapamycin has received Breakthrough Therapy, Fast Track and Orphan Drug designations in mLM.

The company is preparing to commercialize QTORIN rapamycin in the United States itself if approved. Kaupinen said Palvella has identified roughly 400 U.S. centers managing an estimated 15,000 mLM patients through a claims analysis and is using medical-affairs outreach and its BEYOND mLM disease-awareness campaign to build relationships with treatment centers. Palvella has recruited commercial leadership, including Chief Commercial Officer Ashley Kline, who previously led the U.S. launch of Oxervate at Dompé; Jen McDonough, who led market access and patient services at Krystal Biotech; and Senior Vice President of Sales Kent Taylor, previously at Arcutis.